This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Heider, K.-H. Articles by Ponta, H. Search for Related Content PubMed PubMed Citation Articles by Heider, K.-H. Articles by Ponta, H.

Differential Expression of CD44 Splice Variants in Intestinal- and Diffuse-Type Human Gastric Carcinomas and Normal Gastric Mucosa¹

Kernforschungszentrum Karlsruhe, Institut für Genetik, D-76021 Karlsruhe, Germany [K-H. H., P. S.-A., P.H., H. P.], and Universität Würzburg, Institut für Pathologie, D-97080 Würzburg, Germany [J. D., H-K., M-H., H. P. V.]

Immunohistochemical screening of gastric adenocarcinomas from 42 different patients revealed variant CD44 expression in all specimens tested. Adenocarcinomas of the intestinal type were strongly positive for epitopes encoded by variant exons v5 and v6, whereas diffuse-type adenocarcinomas predominantly expressed only exon v5. Normal stomach mucosa was stained by an exon v5-specific monoclonal antibody within the foveolar proliferation zone and on mucoid surface epithelium. Areas of intestinal metaplasia reacted positively with monoclonal antibodies specific for exons v5 and v6.

Analysis of RNA expression revealed dramatic differences between normal mucosa and adenocarcinomas. Whereas in normal epithelium only two CD44 variant RNAs containing exons v5 and/or v6 could be detected, intestinal-type tumors yielded a much more complex pattern of amplification products which hybridized to exons v5 and v6. A similar complex expression pattern of CD44 variants was observed in three cell lines established from intestinal-type tumors. In a sample of a diffuse-type tumor, expression of exon v5, but not v6, could be detected, confirming the data obtained with immunohistochemistry. These differences in variant exon v6 expression observed between diffuse-type and intestinal-type stomach adenocarcinomas establish variant CD44-specific antibodies as a tool in gastric cancer diagnosis and also support the theory of different origins for these tumor types.

¹ This work was supported by Grant He 551-7-1 from the Deutsche Forschungsgemeinschaft, by Boehringer Ingelheim (Bender and Co. GmbH), and by Grant W13-86-Mü-1 from Dr. Mildred Scheel Stiftung-Deutsche Krebshilfe e.V.

² To whom requests for reprints should be addressed, at Kernforschungszentrum Karlsruhe, Institut für Genetik, P.O. Box 3640, D-76021 Karlsruhe, Germany.

Received 3/24/93. Accepted 7/12/93.

This article has been cited by other articles:

				K S Nair, R Naidoo, and R Chetty Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value J. Clin. Pathol., April 1, 2005; 58(4): 343 - 351. [Abstract] [Full Text] [PDF]

				F. F. Solca, A. Baum, E. Langkopf, G. Dahmann, K.-H. Heider, F. Himmelsbach, and J. C. A. van Meel Inhibition of Epidermal Growth Factor Receptor Activity by Two Pyrimidopyrimidine Derivatives J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 502 - 509. [Abstract] [Full Text] [PDF]

				T. N. Alam, M. J. O'Hare, I. Laczko, A. Freeman, F. Al-Beidh, J. R. Masters, and D. L. Hudson Differential Expression of CD44 During Human Prostate Epithelial Cell Differentiation J. Histochem. Cytochem., August 1, 2004; 52(8): 1083 - 1090. [Abstract] [Full Text] [PDF]

				D. R. Colnot, G. J. Ossenkoppele, J. C. Roos, J. J. Quak, R. de Bree, P. K. Borjesson, P. C. Huijgens, G. B. Snow, and G. A. M. S. van Dongen Reinfusion of Unprocessed, Granulocyte Colony-stimulating Factor-stimulated Whole Blood Allows Dose Escalation of 186Relabeled Chimeric Monoclonal Antibody U36 Radioimmunotherapy in a Phase I Dose Escalation Study Clin. Cancer Res., November 1, 2002; 8(11): 3401 - 3406. [Abstract] [Full Text] [PDF]

				D. R. Colnot, J. J. Quak, J. C. Roos, A. van Lingen, A. J. Wilhelm, G. J. van Kamp, P. C. Huijgens, G. B. Snow, and G. A.M.S. van Dongen Phase I Therapy Study of 186Re-Labeled Chimeric Monoclonal Antibody U36 in Patients with Squamous Cell Carcinoma of the Head and Neck J. Nucl. Med., December 1, 2000; 41(12): 1999 - 2010. [Abstract] [Full Text] [PDF]

				A. Wibulswas, D. Croft, I. Bacarese-Hamilton, P. McIntyre, E. Genot, and I. M. Kramer The CD44v7/8 Epitope as a Target to Restrain Proliferation of Fibroblast-Like Synoviocytes in Rheumatoid Arthritis Am. J. Pathol., December 1, 2000; 157(6): 2037 - 2044. [Abstract] [Full Text] [PDF]

				T Gotoda, Y Matsumura, H Kondo, H Ono, A Kanamoto, H Kato, H Watanabe, Y Tachimori, Y Nakanishi, and T Kakizoe Expression of CD44 variants and prognosis in oesophageal squamous cell carcinoma Gut, January 1, 2000; 46(1): 14 - 19. [Abstract] [Full Text] [PDF]

				S. Goodison, K. Yoshida, M. Churchman, and D. Tarin Multiple Intron Retention Occurs in Tumor Cell CD44 mRNA Processing Am. J. Pathol., October 1, 1998; 153(4): 1221 - 1228. [Abstract] [Full Text] [PDF]

				X. Roca, J. L. Mate, A. Ariza, A. M. Munoz-Marmol, C. von Uexkull-Guldeband, I. Pellicer, J. J. Navas-Palacios, and M. Isamat CD44 Isoform Expression Follows Two Alternative Splicing Pathways in Breast Tissue Am. J. Pathol., July 1, 1998; 153(1): 183 - 190. [Abstract] [Full Text] [PDF]

				D. Hudson, J Sleeman, and F. Watt CD44 is the major peanut lectin-binding glycoprotein of human epidermal keratinocytes and plays a role in intercellular adhesion J. Cell Sci., January 5, 1995; 108(5): 1959 - 1970. [Abstract] [PDF]

				Y Matsumura, D Hanbury, J Smith, and D Tarin Non-invasive detection of malignancy by identification of unusual CD44 gene activity in exfoliated cancer cells BMJ, March 5, 1994; 308(6929): 619 - 624. [Abstract] [Full Text]